the aid library

LIST OPTIONS

Filter

2304

Lesotho: DRUGS OF ABUSE ACT OF 2008

Parliament of Lesotho (2008) C2

An Act to repeal the Dangerous Medicines Act of 1973,to ensure the availability of certain drugs for exclusive medical, scientific and related purposes, while preventing their abuse; to prevent the diversion from lawful trade of ... chemicals, controlled equipment and controlled materials for use in the unlawful manufacture of such drugs; to render drug trafficking and related conduct as serious criminal offences and to ensure that trafficking and related conducted as serious criminal offences and to ensure that offenders or suspects are brought to justice; to render certain conduct by drug users as criminal offences, to provide for the treatment and rehabilitation of drug abusing or dependent offenders; to establish the Lesotho Narcotics Bureau; and for related matters. more

External Link

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE... more

Preventing the Spread of an Infectious Disease

Wolters Kluwer; Clinical Drug Information, Inc. and its affiliates andor licensors (2020) C2

Diseases that spread easily have always been around. Sometimes these diseases spread from one person to another person. Sometimes they spread from animals to people. Other times, they spread through germs in the water, soil, food, or air. Some diseases can be prevented or ... with a vaccination, like measles. Other diseases may not have a vaccine or drugs to treat them. Because of this, it is important to prevent the spread of diseases. Last Reviewed Date: 2020-03-18 more

Download (206)

View PDF (215)

HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis

World Health Organization WHO (2020) C_WHO

WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i... more

Download (1565)

View PDF (2399)

The World Medcines situation 2011 Rational use of Medicines

World Health Organization WHO (2011) C_WHO

Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there... more

Download (468)

View PDF (635)

Controlled Substances Dispensing Record Form

Ecumenical Pharmaceutical Network (EPN) (2011) C2

Last revised 2015. Original Word document on: http://www.epnetwork.org/Resources/Standard%20Operating%20Procedure/Controlled%20substances%20dispensing%20record_Form.doc

Download (871)

View PDF (2873)

Nepal: Drugs Act, 2035, (1978)

World Health Organisation (WHO) (2000) C_WHO

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Download (498)

View PDF (1044)

Instruksi Presiden Republik Indonesia Nomor 3 tahun 2002 tentang Penanggulangan Penyalahgunaan dan Peredaran Gelap Narkotika, Psikotropika, Prekursor dan Zat Adiktif Lainnya

President of the Republic of Indonesia (2002) C1

Instruction of the President of the Republic of Indonesia No. 3 of 2002 concerning the Control of Illicit Abuse and Distribution of Narcotics, Psychotropic, Precursors and other Addictive Substances

Download (2979)

View PDF (1166)

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Access to controlled medicines for pain management in the WHO South-East Asia Region

World Health Organisation (WHO) (2023) C_WHO

The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to thes... more

Download (1398)

View PDF (3430)

Preventive chemotherapy in human helminthiasis : coordinated use of anthelminthic drugs in control

World Health Organization (2006) C_WHO

Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers

Mindfulness meditation improves emotion regulation and reduces drug abuse

Tang, Y.Y.; Tang, R.; Posner, M.I. Drug and Alcohol Dependence (2016) CC

Background The core clinical symptoms of addiction include an enhanced incentive for drug taking (craving), impaired self-control (impulsivity and compulsivity), emotional dysregulation (negative mood) and increased stress reactivity. Symptoms related to impaired self-control involve reduced activi... more

Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users: An Integrated Approach

World Health Organization, UNAIDS, United Nations Office on Drugs and Crime (2008)

These policy guidelines provide a strategic approach and new recommendations for integrated TB and HIV services for patients suffering from substance-abuse addiction. The key recommendations fall under three main categories: joint planning, key interventions, and overcoming barriers.

External Link

Programme de bonne gouvernance dans le secteur pharmaceutique, cadre de mise en oeuvre, République du Bénin

Ministère de la Santé Direction de la Pharmacie et des Laboratoires (Dr Léon Kessou; Prosper C. Ahonlonsou WHO (OMS) (2012) C_WHO

Les conséquences néfastes de la mauvaise gestion et les faits de corruption dans le domaine de la santé ont amené l’Organisation mondiale de la Santé (OMS) à mettre en place depuis 2004, un programme de bonne gouvernance qui vise à améliorer les mesures de transparence dans l’exercice... more

External Link

Reimagining the fight against Chagas disease

Novartis (2020) C1

Chagas disease affects approximately 6 million people, mainly in Latin America. Less than 1% of affected individuals receive proper antiparasitic treatment, and current drugs are inadequate to fight the entire spectrum of the disease. Against this b... more

Download (191)

View PDF (346)

Controlled clinical trails in Tuberculosis

A. Jindani, A. Nunn, D. A. Enarson International Union Against Tuberculosis and Lung Disease (2004)

A Guide For Multicentre Trials in High-Burden Countries

External Link

Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms

C. Chilvers, M. Dewey, K. Fielding, et al. (2001) CC

BMJ 2001;322:1–5

The fight against fake drugs by NAFDAC in Nigeria

The fight against fake drugs by NAFDAC in Nigeria Olike Chinwendu KIT (Royal Tropical Institute) Development Policy & Practice Vrije Universiteit Amsterdam (2008) CC

Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.

Download (309)

View PDF (220)

Standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) for management of convulsive epilepsy in adults and children

World Health Organization (2012) C_WHO

Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?

A living WHO guideline on drugs for covid-19 recommended

A living WHO guideline on drugs for covid-19
recommended